• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·BIOWKS.ST
Share

Bio-Works Technologies AB Stocks

SEK 3.28Last Updated 27.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

SEK 27.39M

SEK 3.28
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bio-Works Technologies AB (publ) is a biotechnology company that specializes in the research, development, production, and distribution of agarose-based separation products. These sophisticated solutions are designed to facilitate the purification of proteins, peptides, and other biomolecules, with a primary focus on the Swedish market. Their comprehensive product portfolio encompasses items such as activated and affinity resins, BabyBio columns, immobilized metal-ion affinity chromatography (IMAC) resins, ion exchange resins, OptioBio glass columns, screening kits, and size exclusion chromatography (SEC) resins. These offerings find use across various applications, including those concerning antibodies, His-tagged proteins, other proteins, peptides, oligonucleotides, and in the purification of viruses and vaccine development. Established in 2006, the company is headquartered in Uppsala, Sweden.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 12:29

Samsung and SK Hynix Plummeted Ahead of Earnings Reports: News from China Fueled Investor Fears

28.07.2026 12:00

Is Cartier the New Birkin? Investors Are Looking for the Next Big Thing in the World of Luxury

28.07.2026 10:42

Top Stories This Morning: New U.S. Rules for AI, a Plunge in Chipmakers’ Stocks and the South Korean Stock Market

28.07.2026 09:00

Rivian is benefiting from the growth of robotaxis. One analyst expects the stock to rise 26%.

28.07.2026 08:00

Germany will cut spending on ammunition. Which company will be negatively affected by this?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026